Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18422360 | 1.00 | CA1 (0.50) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL18422361 | 0.90 | CA1 (0.49) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL18422362 | 0.90 | CA1 (0.49) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL18418134 | 0.89 | CA1 (0.43) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL18418159 | 0.89 | CA1 (0.43) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL18418142 | 0.85 | ALDH1A1 (0.41) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL21391904 | 0.85 | ALDH1A1 (0.41) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL18480978 | 0.84 | CA1 (0.54) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL22417666 | 0.83 | CA1 (0.39) | CA1CA2HDAC4HDAC6LMNA | |
| SCHEMBL22417680 | 0.81 | CA1 (0.41) | CA1CA2HDAC4HDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | MAKSCIENTIFIC, LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | MAKSCIENTIFIC, LLC | 2019-05-23 | — | — | US | disclosed |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | ABHD6, FAAH, FAAH2 | CA1 4117/4885CA2 4032/4885HDAC4 3790/4885 |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | ABHD6, FAAH, FAAH2 | CA1 4117/4885CA2 4032/4885HDAC4 3790/4885 |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | CA1 475/4885CA2 1148/4885HDAC4 1821/4885 |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | CA1 475/4885CA2 1148/4885HDAC4 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.